Flupentixol/melitracen (trade name Frenxit, Franxit, Placida, Deanxit, Anxidreg, Danxipress, Mocalm) is a combination of two psychoactive agents flupentixol and melitracen. It is designed for short term usage only. It is produced by Lundbeck.[1]
Flupentixol is a thiazolyl (thioanthracene) antipsychotic, and melitracen is a tricyclic antidepressant. Low dose Flupentixol (0.5mg-3mg) has antidepressant and anti-anxiety effects, while melitracen has antidepressant effect. The mixture of the two components is used to treat mild to moderate mental disorders.
Flupentixol acts as a dopamine 1 and 2 receptor antagonist and melitracen acts in similar way to other tricyclic antidepressants blocking the reuptake of serotonin and norepinephrine in presynaptic terminals.
| Depixol | Flupentixol decanoate | Deep Intramuscular Injection | 20 mg/mL Solution[3] (Amount injected varies depending on prescribed dose) | Lundbeck | |
| Deanxit | Flupentixol, Melitracen | Oral, Tablet form | 0.5 mg Flupentixol, 10 mg Melitracen[4] (per tablet) | Lundbeck |
Adult: Per tablet contains flupentixol 0.5 mg and melitracen 10 mg: 1 tablet in the morning and at midday. May double morning dose in severe cases. Not to exceed 4 tablets daily.
Elderly: Per tablet contains flupentixol 0.5 mg and melitracen 10 mg: 1 tablet in the morning. For severe cases: 1 tablet in the morning and at midday.
Circulatory collapse, depressed level of consciousness due to any cause, Coma. Severe depression requiring hospitalization or electroconvulsive therapy. Not recommended for use in states of excitement or overactivity.
Unsafe in porphyria. Caution when used in patients with epilepsy; Parkinson's disease; narrow angle glaucoma; prostatic hypertrophy; hypothyroidism; hyperthyroidism; liver disease; cardiac disease or arrhythmias; severe respiratory disease; renal failure; myasthenia gravis; phaeochromocytoma. Patients with hypersensitivity to thioxanthenes or other antipsychotics. Close monitoring for changes in behaviour, suicidal thoughts or clinical worsening during the initial part of the treatment is recommended. May impair control of diabetes; monitor blood glucose in diabetics.
Drowsiness, dry mouth, constipation, vomiting, dyspepsia, diarrhoea, abdominal pain, nausea, flatulence. Extrapyramidal effects, especially in the initial phase of the treatment. Tachycardia, palpitations, prolonged QT interval, hypotension. Thrombocytopenia, neutropenia, leukopenia, agranulocytosis. Dyspnoea, myalgia, muscle rigidity, micturition disorder, urinary retention. Increased appetite and weight. Abnormal glucose tolerance and LFTs. Insomnia, depression, nervousness, agitation, decreased libido.
Increased risk of adverse effects when used with alcohol. May potentiate the effects of general anaesthetics and anticoagulants, and prolong the action of neuromuscular blockers. May increase anticholinergic effects of atropine and drugs with anticholinergic activity. May increase risk of neurotoxicity when used with sibutramine or lithium. Avoid concurrent usage with drugs that cause QT prolongation or cardiac arrhythmias. May inhibit metabolism of TCAs. May antagonise effects of adrenaline and sympathomimetics, and reverse antihypertensive effects of guanethidine.
Flupentixol inhibits dopamine-mediated effects by blocking postsynaptic dopamine receptors in the CNS.
Melitracen is a TCA with anxiolytic properties. At low doses, it has activating properties. It is also a bipolar thymoleptic.
Absorption: Flupentixol: Readily absorbed in the GI tract.
Distribution: Flupentixol: >95% bound to plasma proteins; widely distributed in the body and crosses the blood brain barrier.
Metabolism: Flupentixol: Extensively hepatic metabolism.
Excretion: Flupentixol: Excreted in urine and faeces in the form of many metabolites.
N06AA14 - melitracen ; Belongs to the class of non-selective monoamine reuptake inhibitors. Used in the management of depression.
N05AF01 - flupentixol ; Belongs to the class of thioxanthene derivatives antipsychotics.
Brand names include: